Gilead Sciences Articles
Gilead's aztreonam meets Ph III endpoint
22 December 2006
Gilead submits US NDA for ambrisentan
22 December 2006
November a lackluster month for biotechnology stocks, says Burrill
18 December 2006
Gilead subpoenaed over HIV drugs
18 December 2006
elbion AG merges with 4AZA Bioscience NV
11 December 2006
Gilead extends Myogen offer deadline to Nov 13
13 November 2006
Gilead's 3rd-qtr losses hit $52M on Corus buy
30 October 2006
Stock Commentary - New York week to Oct 9, 2006
16 October 2006
HIV drug Atripla submitted to EMEA
16 October 2006
Stock Commentary - Europe - week to Oct 2, 2006
9 October 2006
B-MS and Gilead Sci sign Atripla accord
9 October 2006
Gilead signs eight generic Viread licenses
2 October 2006
Gilead exercises option to buy Corus for $365M
14 August 2006
Stock Commentary - New York week to July 24, 2006
24 July 2006
Gilead to donate $1.1M a year to Czech IOCB
24 July 2006
Atripla approved by FDA for use in HIV-1 therapy
17 July 2006
Japan stock market week to June 19, 2006
26 June 2006
Gilead to buy Degussa's Raylo unit
12 June 2006
India overtakes South Africa for HIV/AIDS
12 June 2006
Diatos acquires DaunoXome from Gilead for $4.7M
15 May 2006
Gilead's 1st-qtr sales reach $692.9M, up 61%
15 May 2006
B-MS and Gilead enter deal for HAART tablet
8 May 2006
Gilead prices $1.2B convertible notes
1 May 2006
New human resources head at Gilead Sciences
24 April 2006
Gilead announces GS 9137 Ph I/II study data
20 February 2006
Gilead launches "Stop Hep B" campaign
20 February 2006
Gilead reports $2B revenue in 2005, up 53%
6 February 2006
Good efficacy for Gilead Sci's ARV combo
30 January 2006
Gilead/B-MS' HIV combo drug is bioequivalant
16 January 2006
Gilead sees positive results in Ph I/II trials of HIV drug
16 January 2006
Gilead cuts Viread, Truvada prices to LDCs
5 September 2005
Stock Commentary - New York week to Aug 15
22 August 2005
Gilead's Truvada fails bioequivalence study
22 August 2005
Gilead/Achillion start dosing in GS9132 trial
22 August 2005
Promotions at Gilead Sciences
15 August 2005
Gilead's Truvada HIV combo not bioequivalent
15 August 2005
Gilead's 2nd-qtr revenues up 55%
1 August 2005
Gilead starts Ph III program of HBV candidate
25 July 2005
Gilead to pull out of Tamiflu deal with Roche
4 July 2005
Gilead initiates Ph I/II trial of HIV drug
27 June 2005
Gilead Sci/Aspen in marketing deal
16 May 2005
Stock Commentary - New York
28 April 2005
Truvada lifts 1st qtr for Gilead Sciences
25 April 2005
Gilead gets all clear for JTK-303 deal
11 April 2005
Brazil license request to HIV/AIDS drugmakers
28 March 2005
Truvada get EU market approval
7 March 2005
Gilead reports 48-wk data from HIV study
14 February 2005
B-MS and Gilead set up JV to market triple AIDS drugs
10 January 2005
Stock Commentary - New York
1 November 2004
Gilead's 3rd-qtr 2004 revenues rocket 63%
1 November 2004
Gilead discontinues development of GS 9005 and GS 7340
1 November 2004
Gilead and Genelabs in HCV accord
11 October 2004
Kevin Young joins Gilead as exec VP, commercial operations
27 September 2004
In August, biotech emerges from doldrums, but uncertainty persists: Burrill review
13 September 2004
Warning over UK NICE Tamiflu guidance
6 September 2004
Gilead board sets up stock trading plan
23 August 2004
Gilead sees sales jump 30% for 2nd-qtr
9 August 2004
US FDA clears way for Gilead's Truvada
9 August 2004
Eyetech sees losses grow on Macugen development costs
2 August 2004
Stock Commentary - New York
31 May 2004
Pharma acts on US fast- track plan for FDCs
24 May 2004
Japan Tobacco and Torii introduce new HIV drug in Japan
19 April 2004
Viread/Emtriva tablet filed in USA and EU
22 March 2004
Preliminary data from three-year Viread trial
16 February 2004
Stock Commentary - New York
9 February 2004
Brazil wins major HIV/ AIDS drug price cuts
26 January 2004
Gilead files IND for GS 9005 in HIV
19 January 2004
Gilead files $500M shelf registration
5 January 2004
Stock Commentary - New York
10 November 2003
Gilead soars on strong HIV drug sales
10 November 2003
Gilead's Emtriva wins EU approval
3 November 2003
NICE plans six new pharma guidelines for NHS in England/Wales
20 October 2003
New NICE guidances for England and Wales
6 October 2003
Stock Commentary - New York
29 September 2003
Chimerix gains rights to Gilead's cidofovir
22 September 2003
Gilead buys Foster City campus for $123M
22 September 2003
Chimerix gets $36M NIH grant to develop smallpox therapy
15 September 2003
Gilead starts Viread/Emtriva combi study
18 August 2003
Gilead signs deal with Japan Tobacco
11 August 2003
Gilead's Emtriva on track for EU approval
4 August 2003
Gilead's Emtriva shows efficacy at 60 wks
28 July 2003
Stock Commentary - New York
21 July 2003
Gilead Sciences set to beat expectations
21 July 2003
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Is failure to adopt business process management putting the pharma industry at risk?
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
